{
    "nct_id": "NCT03761160",
    "official_title": "Mobile Health App to Mitigate the Metabolic Effects of Androgen Deprivation Therapy: A Randomize Pilot Trial in Men Newly Treated With Androgen Deprivation Therapy",
    "inclusion_criteria": "Phase 1\n\n* All recruited participants must have owned a smartphone for >1 year\n* English-speaking.\n* Patients with prostate cancer aged between 40-75 years will be considered.\n* No specific timeframe after prostate cancer diagnosis will be required for these patients.\n* No limitations regarding their disease characteristics will be imposed (e.g. metastatic disease).\n* Patients may or may not be currently receiving treatment Staff members will be recruited from\n* Dana-Farber Cancer Institute Department of Medical Oncology,\n* Brigham and Women's Hospital, Department of Surgery. Staff members aged between 40-75 years old will be considered. Phase 2\n* Men diagnosed with prostate cancer presenting to DF/BWHCC\n* About to initiate ADT for the first time will be considered.\n* Age range 40-75-years\n* The ability to walk 400 m\n* Medical clearance from their primary physician\n* English speaking\n* Cognitively alert\n* Literate\n* Ability to read or hear with or without contacts/glass and hearing aid\n* Ownership of a smartphone for >1yr\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 40 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "* Men who have been under a rigorous structured exercise regime, such as individuals who engage in more than 900 minutes of moderate physical activity per week in the last 6 months will not be considered\n* Post-ADT treatment\n* Planned systemic chemotherapy\n* Planned treatment with abiraterone or enzalutamide\n* Bone metastases\n* Acute illness\n* Any musculoskeletal, cardiovascular, or neurologic disorders that could inhibit or put them at risk from exercising\n* Subordinates to the PI",
    "miscellaneous_criteria": ""
}